knowledge -WSS

knowledge

author：knowledge 2025-10-01 12:35:29 - browse：7

Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.

For more on what we cover, here’s the news on Dewpoint Therapeutics; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： White House drug shortages task force keeps mum with Congress

WSS

Kim Kardashian sparks debate on benefits of full

Covid's long

Prime Medicine, Myeloid Therapeutics clash over genome

How to keep neuroscience’s past racism from being its future

CRISPR gene editing developments we’re watching in 2024

Maui funeral service workers on devastation of fires: 'I'm in shock'

leisure time

knowledge

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Prime Medicine, Myeloid Therapeutics clash over genome

New air purifier tech could be key to improving indoor air quality

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

How one medical school became remarkably diverse

Prime Medicine, Myeloid Therapeutics clash over genome

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Keeping primary care docs in field isn't impossible, says AAFP CEO

Activists slam private health insurers over coverage restrictions

Target recalls 2.2 million additional candles due to laceration, burn hazards

focus

TB outbreak tied to bone grafts underscores testing shortcomings

CRISPR gene editing developments we’re watching in 2024

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

David Ricks of Eli Lilly: best biopharma CEO of 2023

Christmas in the PICU brings some surprising joy

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

leisure time

Wikipedia

focus

knowledge